Clinical Trial Update: Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Vigil in combination with nivolumab for advanced/metastatic non-small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Neoplasms
• Non-small Cell Lung Cancer

Drugs mentioned

• Vigil
• nivolumab (nivolumab)

Snippet

Sponsor: Gradalis, Inc. | Conditions: Advanced Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer | Phase 2 | Status: WITHDRAWN